Key result
Novel Lp(a)-lowering therapies show promising phase 2 efficacy with phase 3 trials ongoing for residual risk.
This review highlights the pathogenic role of Lipoprotein(a) in cardiovascular disease and summarizes the promising development of novel RNA-targeted therapies currently in phase 3 trials.
Despite adequate primary and secondary prevention of cardiovascular events, significant residual risk remains. Part of this risk has been attributed to lipoprotein(a) (Lp{a}). This is a genetically determined lipoprotein that has been linked to cardiovascular disease. Its variability and pathogenicity are attributed to the unique apolipoprotein(a) (apo{a}) within the molecule. This protein has been related to proatherogenic, proinflammatory, prothrombotic, and procalcific mechanisms that favor cardiovascular disease (CVD). Although it is recognized as a causal factor in disease, there are currently no approved therapeutics targeting this lipoprotein. Current management focuses on aggressive control of traditional cardiovascular risk factors. Novel therapeutics targeting Lp(a), including small interfering ribonucleic acids (siRNAs) and antisense oligonucleotides (ASOs), showed promising results in phase 2 trials. Multiple therapeutics are currently undergoing phase 3 trials, promising to bring a solution to this unsolved issue.
No takes yet. Share an insight, caveat, or question.
Sotela et al. (2026) conducted a review in Cardiovascular disease. Novel therapeutics targeting Lp(a) was evaluated. Novel therapeutics targeting lipoprotein(a), including siRNAs and ASOs, show promising results in phase 2 trials, with multiple phase 3 trials currently underway to address residual cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: